Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OraSure Technologies to Present at the Raymond James 38th Annual Institutional Investors Conference

OSUR

BETHLEHEM, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 38th Annual Institutional Investors Conference in Orlando, Florida.  The conference will be simultaneously webcast over the Internet.

Mr. Michels is scheduled to speak on March 6, 2017, at approximately 8:40 AM Eastern Time (5:40 AM Pacific Time).  Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com, and clicking on the Investor Info link.  A replay of the webcast will be available on OraSure Technologies’ web site for seven days.  Alternatively, you can access the live webcast of the presentation via the following link: http://wsw.com/webcast/rj104/osur

About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. 

For more information on OraSure Technologies, please visit www.orasure.com.

Company contact: Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com

Primary Logo